☆ 4.6 Review

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang et al.

Summary: The study evaluated the efficacy and safety of adebrelimab in combination with standard chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The results showed that the addition of adebrelimab significantly improved overall survival and had an acceptable safety profile. Therefore, the combination of adebrelimab and chemotherapy may be a new treatment option for ES-SCLC patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Update in TIGIT Immune-Checkpoint Role in Cancer

Tiziana Annese et al.

Summary: This article discusses the interaction between tumor cells and T cells, with a focus on the role of TIGIT in immune cells. It proposes therapeutic strategies for cancer treatment by targeting the TIGIT pathway.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

L. Paz-Ares et al.

Summary: In extensive-stage small-cell lung cancer (ES-SCLC), durvalumab plus EP continues to improve overall survival (OS), while durvalumab plus tremelimumab plus EP shows numerical improvement but does not reach statistical significance.

ESMO OPEN (2022)

添加到收藏夹

Article Oncology

Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing

Joseph B. Hiatt et al.

Summary: This study found that the combination of LSD1 inhibitor and PD-1 inhibitor can enhance the treatment response in SCLC, leading to increased CD8 T cell infiltration, tumor growth inhibition, and increased MHC-I expression, thus increasing the killing activity of tumor-specific T cells.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Impact of underrepresented populations on clinical outcomes of chemo-immunotherapy for extensive-stage small cell lung cancer: Real-world prospective cohort study.

Motohiro Tamiya et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.

Dawei Chen et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).

Charles M. Rudin et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death- Ligand 1 Blockade Resistance in SCLC

Evelyn M. Nguyen et al.

Summary: This study reveals that targeted inhibition of LSD1 restores MHC-I expression in SCLC, induces immune activation, and enhances the anti-tumor immune response to ICB. The findings suggest a potential combinatory use of LSD1 inhibitors with ICB to improve the therapeutic outcomes in SCLC.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) plus carboplatin (CB)/cisplatin (CP) plus etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain

M. R. Garcia Campelo et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial

Ying Cheng et al.

Summary: This study evaluated the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with extensive-stage SCLC. The results showed that serplulimab plus chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone, supporting its use as a first-line treatment for patients with previously untreated extensive-stage SCLC.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Oncology

OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

C.M. Rudin et al.

Journal of Thoracic Oncology (2022)

添加到收藏夹

Article Oncology

OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer

H. Borghaei et al.

Journal of Thoracic Oncology (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer

Lingling Li et al.

Summary: The study demonstrates the efficacy of rechallenge of PD-1/PD-L1 inhibitors in SCLC patients, especially in the first-line initial immunotherapy subgroup or patients with SD/PD response to the initial immunotherapy.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study

Jingjing Qu et al.

Summary: This study demonstrates that adding PD-L1 inhibitors to chemotherapy can significantly improve progression-free survival (PFS) and overall survival (OS) in patients with extensive-stage small-cell lung cancer (ES-SCLC), and shows its safety without additional adverse events.

JOURNAL OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function

Afshin Dowlati et al.

Summary: This study found that mutations in the RB1 gene are associated with survival outcomes in small-cell lung cancer (SCLC) patients treated with immune checkpoint blockade (ICB). RB1 mutant tumors showed downregulated expression of immune-related genes and an immune exclusion phenotype. SCLC patients with wild-type RB1 status or lower RB1 gene loss-of-function signature scores have better outcomes with ICB monotherapy.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Bradford A. Perez et al.

Summary: The study investigated the addition of ipilimumab and nivolumab after thoracic radiation therapy for patients with extensive stage small cell lung cancer, showing higher than expected overall survival rates. Increased CD3+CD8+ tumor infiltration was associated with favorable outcomes in terms of progression-free survival and overall survival.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Oncology

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

Carl M. Gay et al.

Summary: Despite the heterogeneity of small cell lung cancer (SCLC), four subtypes have been identified based on tumor expression data, each showing different responses to treatment. SCLC-I subtype benefits the most from immunotherapy, while other subtypes have vulnerabilities to different inhibitors. Matching tumor subtype to therapy and manipulating subtype switching during treatment may enhance response depth and duration for SCLC patients.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman et al.

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

OA07.03 A Phase II Study of Frontline Rucaparib + Nivolumab in Platinum Sensitive ES SCLC: Interim Analysis

A. Chauhan et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Taofeek K. Owonikoko et al.

Summary: Maintenance therapy with nivolumab plus ipilimumab did not prolong overall survival (OS) for patients with extensive-disease small-cell lung cancer (ED-SCLC) who did not progress on first-line chemotherapy. However, there may be a benefit of nivolumab plus ipilimumab in patients with a tumor mutational burden of >= 13 mutations per megabase. The rates of grade 3-4 treatment-related adverse events were highest in the nivolumab plus ipilimumab group.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

Navin R. Mahadevan et al.

Summary: A subset of SCLC patients exhibit durable response to immune checkpoint blockade by upregulating MHC I after losing neuroendocrine differentiation, which can be enhanced through EZH2 inhibition and STING agonism, leading to immune rejection of SCLC in preclinical models.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Mark A. Socinski et al.

Summary: The final analysis of IMpower150 study showed a numerical OS improvement with ACP compared to BCP in metastatic nonsquamous NSCLC patients, while ABCP demonstrated continued OS improvement in all patients.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer

Nitin Roper et al.

Summary: This study identifies elevated Notch signaling as a significant predictor of clinical benefit in immune checkpoint blockade (ICB) for relapsed small cell lung cancer (SCLC) patients. Activation of Notch signaling induces a low NE phenotype, leading to increased expression of antigen processing and presentation machinery (APM) genes and improved intrinsic tumor immunity.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

Marian L. Burr et al.

CANCER CELL (2019)

添加到收藏夹

Article Medicine, General & Internal

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

Lydia Meder et al.

CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

David R. Gandara et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Immunology

Improving immune-vascular crosstalk for cancer immunotherapy

Yuhui Huang et al.

NATURE REVIEWS IMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer

Karen McColl et al.

ONCOTARGET (2017)

添加到收藏夹

Review Oncology

Small-cell lung cancer: what we know, what we need to know and the path forward

Adi F. Gazdar et al.

NATURE REVIEWS CANCER (2017)

添加到收藏夹

Article Oncology

ESMO-Magnitude of Clinical Benefit Scale version 1.1

N. I. Cherny et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

Ben J. Slotman et al.

LANCET (2015)

添加到收藏夹

Review Immunology

Alternative antigen processing for MHC class I: multiple roads lead to Rome

Claudia C. Oliveira et al.

FRONTIERS IN IMMUNOLOGY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Retinoblastoma Protein Potentiates the Innate Immune Response in Hepatocytes: Significance for Hepatocellular Carcinoma

Jack Hutcheson et al.

HEPATOLOGY (2014)

添加到收藏夹

Article Oncology

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

Antonio Rossi et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Yuhui Huang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

添加到收藏夹

Article Oncology

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Mark A. Socinski et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Small cell lung carcinoma (SCLC): the angiogenic phenomenon

M Lucchi et al.

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.